• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.

作者信息

Orlandi A, Mastrantoni L, Bria E, Tortora G

机构信息

Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

出版信息

Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3.

DOI:10.1016/j.annonc.2024.05.544
PMID:38838845
Abstract
摘要

相似文献

1
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3.
2
Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):747-748. doi: 10.1016/j.annonc.2024.05.543. Epub 2024 Jun 3.
3
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.阿贝西利联合非甾体芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌的初始治疗：MONARCH 3 的最终总生存结果。
Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8.
4
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.阿贝西利联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性的绝经前激素受体阳性晚期乳腺癌：MONARCH 2 试验的亚组分析。
Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2.
5
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.MONARCH 3 研究：阿贝西利联合芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌初始内分泌治疗的疗效和安全性
Oncologist. 2020 Sep;25(9):e1346-e1354. doi: 10.1634/theoncologist.2020-0084. Epub 2020 Jun 24.
6
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.阿贝西利单药或联合内分泌治疗晚期乳腺癌患者循环肿瘤 DNA 中基线和获得性基因组改变的图谱。
Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573.
7
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.阿贝西利联合曲妥珠单抗和（或）氟维司群对比曲妥珠单抗联合标准治疗化疗用于激素受体阳性、HER2 阳性晚期乳腺癌患者（monarcHER）：一项随机、开放标签、二期临床试验。
Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27.
8
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.阿贝西利联合内分泌治疗对比化疗用于 HR+/HER2-转移性乳腺癌患者既往帕博西利进展后的治疗：中国单中心真实世界研究。
Cancer Med. 2024 May;13(10):e7249. doi: 10.1002/cam4.7249.
9
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
10
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.在中国绝经前和绝经后女性中，初始使用瑞博西尼联合内分泌治疗HR+/HER2-晚期乳腺癌：一项2期随机研究的主要结果
Cancer Med. 2024 Aug;13(15):e7408. doi: 10.1002/cam4.7408.